Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic adjuvant therapy for breast cancer.

D Tripathy1, I C Henderson

  • 1Department of Medicine, Mt. Zion Medical Center, University of California, San Francisco 94120-7921.

Current Opinion in Oncology
|December 1, 1992
PubMed
Summary

Systemic therapy for operable breast cancer can delay recurrence and improve survival. Adjuvant chemotherapy and tamoxifen have shown benefits, but optimal use, especially for node-negative cases, requires further definition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy.

ESMO open·2025
Same author

Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆.

ESMO open·2024
Same author

Distress and inflammation are independently associated with cancer-related symptom severity.

Comprehensive psychoneuroendocrinology·2024
Same author

Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Correction: The effect of interface heterogeneity on zinc metal anode cyclability.

Journal of materials chemistry. A·2024
Same author

The effect of interface heterogeneity on zinc metal anode cyclability.

Journal of materials chemistry. A·2024

Area of Science:

  • Oncology
  • Clinical Trials
  • Breast Cancer Research

Background:

  • Systemic therapy for operable breast cancer aims to delay recurrence and improve survival.
  • Adjuvant chemotherapy and tamoxifen have been used for decades, but consensus on their optimal application remains limited.
  • Large-scale meta-analyses of clinical trials are crucial for identifying treatment benefits in specific patient subgroups.

Purpose of the Study:

  • To review the established and emerging roles of adjuvant systemic therapies in early-stage breast cancer.
  • To discuss the current understanding of chemotherapy and hormonal therapy use based on menopausal status and estrogen receptor status.
  • To highlight ongoing research into new agents, regimens, and treatment strategies, including those for node-negative breast cancer.

Main Methods:

Related Experiment Videos

  • Analysis of data from numerous controlled clinical trials in early-stage breast cancer.
  • Examination of outcomes related to adjuvant chemotherapy and hormonal therapy (tamoxifen).
  • Review of current treatment guidelines and emerging research trends.

Main Results:

  • Systemic adjuvant therapies demonstrate a delay in recurrence and an improvement in overall survival for breast cancer patients.
  • Established treatment protocols exist for node-positive patients (chemotherapy for premenopausal, tamoxifen for postmenopausal with ER+ tumors).
  • Evidence suggests small but significant benefits from adjuvant treatment, though risks and benefits require further clarification, particularly for node-negative disease.

Conclusions:

  • Adjuvant systemic therapies offer significant benefits in delaying breast cancer recurrence and improving survival.
  • While treatment strategies are defined for many node-positive patients, the management of node-negative breast cancer remains an area of ongoing investigation and debate.
  • Continued research into novel agents, treatment combinations, and personalized approaches is essential for optimizing breast cancer care.